

WE CLAIM:

1. A method of treating chronic pain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises amino acid sequences LCDR1, LCDR2, and LCDR3, and the HCVR comprises amino acid sequences HCDR1, HCDR2, and HCDR3, wherein LCDR1 is SEQ ID NO:4, LCDR2 is SEQ ID NO:5, LCDR3 is SEQ ID NO:6, HCDR1 is SEQ ID NO:1, HCDR2 is SEQ ID NO:2, and HCDR3 is SEQ ID NO:3.
2. A method of treating chronic osteoarthritis pain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises amino acid sequences LCDR1, LCDR2, and LCDR3, and the HCVR comprises amino acid sequences HCDR1, HCDR2, and HCDR3, wherein LCDR1 is SEQ ID NO:4, LCDR2 is SEQ ID NO:5, LCDR3 is SEQ ID NO:6, HCDR1 is SEQ ID NO:1, HCDR2 is SEQ ID NO:2, and HCDR3 is SEQ ID NO:3.
3. A method of treating chronic diabetic peripheral neuropathy pain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises amino acid sequences LCDR1, LCDR2, and LCDR3, and the HCVR comprises amino acid sequences HCDR1, HCDR2, and HCDR3, wherein LCDR1 is SEQ ID NO:4, LCDR2 is SEQ ID NO:5, LCDR3 is SEQ

ID NO:6, HCDR1 is SEQ ID NO:1, HCDR2 is SEQ ID NO:2, and HCDR3 is SEQ ID NO:3.

- 5 4. A method of treating chronic low back pain in a subject in need thereof,
 comprising administering to the subject a therapeutically effective amount of
 an antibody comprising a light chain and a heavy chain, wherein the light
 chain comprises a light chain variable region (LCVR) and the heavy chain
 comprises a heavy chain variable region (HCVR), wherein the LCVR
10 comprises amino acid sequences LCDR1, LCDR2, and LCDR3, and the
 HCVR comprises amino acid sequences HCDR1, HCDR2, and HCDR3,
 wherein LCDR1 is SEQ ID NO:4, LCDR2 is SEQ ID NO:5, LCDR3 is SEQ
 ID NO:6, HCDR1 is SEQ ID NO:1, HCDR2 is SEQ ID NO:2, and HCDR3 is
 SEQ ID NO:3.
- 15
5. The method according to any one of Claims 1-4, wherein the amino acid
 sequence of the LCVR is SEQ ID NO:9 or SEQ ID NO:10.
- 20
6. The method according to any one of Claims 1-4, wherein the amino acid
 sequence of the HCVR is SEQ ID NO:7.
- 25
7. The method according to any one of Claims 1-4, wherein the amino acid
 sequence of the LCVR is SEQ ID NO:9 and the amino acid sequence of the
 HCVR is SEQ ID NO:7.
- 30
8. The method according to any one of Claims 1-4, wherein the amino acid
 sequence of the light chain is SEQ ID NO:13 or SEQ ID NO:14.

9. The method according to any one of Claims 1-4, wherein the amino acid sequence of the heavy chain is SEQ ID NO:12.
- 5 10. The method according to any one of Claims 1-4, wherein the antibody comprises two light chains wherein the amino acid sequence of each light chain is SEQ ID NO:13, and two heavy chains wherein the amino acid sequence of each heavy chain is SEQ ID NO:12.
- 10 11. The method according to any one of Claims 1-4, wherein the antibody comprises two light chains wherein the amino acid sequence of each light chain is SEQ ID NO:14, and two heavy chains wherein the amino acid sequence of each heavy chain is SEQ ID NO:12.
- 15 12. The method according to any one of Claims 1-4, wherein the dose of antibody is a 750mg starting dose, followed by a 500 mg dose every 2 weeks, for as long as the patient needs treatment for pain.
- 20 13. The method according to any one of Claims 1-4 wherein the chronic pain is refractory to two or more prior monotherapy and/or dual therapy treatment regimens.
- 25 14. An antibody comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises amino acid sequences LCDR1, LCDR2, and LCDR3, and the
- 30 HCVR comprises amino acid sequences HCDR1, HCDR2, and HCDR3, wherein LCDR1 is SEQ ID NO:4, LCDR2 is SEQ ID NO:5, LCDR3 is SEQ

ID NO:6, HCDR1 is SEQ ID NO:1, HCDR2 is SEQ ID NO:2, and HCDR3 is SEQ ID NO:3, for use in the treatment of chronic pain.

- 5 15. The antibody for use according to claim 14 wherein the chronic pain is selected from the group consisting of chronic osteoarthritis pain, chronic diabetic neuropathy pain, and chronic low back pain.
- 10 16. The use according to Claims 14 or 15, wherein the amino acid sequence of the LCVR is SEQ ID NO:9 or SEQ ID NO:10.
- 15 17. The use according to Claims 14 or 15, wherein the amino acid sequence of the HCVR is SEQ ID NO:7.
18. The use according to Claims 14 or 15, wherein the amino acid sequence of the LCVR is SEQ ID NO:9 and the amino acid sequence of the HCVR is SEQ ID NO:7.
- 20 19. The use according to Claims 14, wherein the amino acid sequence of the light chain is SEQ ID NO:13 or SEQ ID NO:14.
- 25 20. The use according to Claims 14, wherein the amino acid sequence of the heavy chain is SEQ ID NO:12.
- 30 21. The use according to Claims 14, comprising two light chains, wherein the amino acid sequence of each light chain is SEQ ID NO:13, and two heavy chains, wherein the amino acid sequence of each heavy chain is SEQ ID NO:12.

22. The use according to Claims 14, comprising two light chains wherein the amino acid sequence of each light chain is SEQ ID NO:14, and two heavy chains wherein the amino acid sequence of each heavy chain is SEQ ID NO:12.
23. The use according to claim and of claims 14-22, wherein the chronic pain is chronic osteoarthritis pain.
24. The use according to claim and of claims 14-22, wherein the chronic pain is chronic diabetic peripheral neuropathy pain.
25. The use according to claim and of claims 14-22, wherein the chronic pain is chronic low back pain.
26. The use according to any one of claims 14 – 25, wherein the dose of antibody is a 750mg starting dose, followed by a 500 mg dose every 2 weeks, for as long as the patient needs treatment for pain.
27. The use according to any one of claims 14 – 25, wherein the chronic pain is refractory to two or more prior monotherapy and/or dual therapy treatment regimens.